Galapagos NV Expands U.S. CAR-T Therapy Production

Galapagos NV (GLPG) has released an update.

Galapagos NV has partnered with Blood Centers of America to boost its U.S. expansion by enhancing the manufacturing and availability of its innovative CAR-T cell therapies. This strategic collaboration aims to streamline Galapagos’ decentralized CAR-T production, ensuring faster delivery and better access to potentially life-saving treatments for cancer patients. The alliance is poised to support upcoming pivotal trials and future commercial manufacturing, marking a significant advancement for Galapagos’ U.S. growth strategy.

For further insights into GLPG stock, check out TipRanks’ Stock Analysis page.